Sunshine Biopharma Inc (SBFM) Stock AnalysisSBFMSunshine Biopharma Inc

Sunshine Biopharma Inc. is a pharmaceutical company engaged in offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The Company operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Sunshine Biopharma Inc is not a good buy right now due to its significant decline in stock price and ongoing financial losses. The current price is $2.70, which is a staggering 98.94% lower than its year-to-date high, and the company reported a net income loss of -1,564,048 USD in Q2 2026. Additionally, the RSI is at 29.9, indicating that the stock is oversold, but this does not guarantee a price recovery in the near term.